PLSE Share Price Performance
US$34.25
19.52 (132.52%)
11.7% overvalued intrinsic discount
US$30.67
Fair Value
Price US$34.25
AnalystConsensusTarget US$30.67
AnalystHighTarget US$35.00
Fair ValueUS$30.67
Share Pricen/a
Narrative Update • Jul 29
Pulse Biosciences, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
PLSE Community Narratives
AN
Fair Value
·Fair Value US$30.67 11.7% overvalued intrinsic discount
Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value
·Fair Value US$35 2.1% undervalued intrinsic discount
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Early Thyroid And Cardiac Applications Will Establish A Powerful Medical Device Platform
Pulse Biosciences is trying to turn its early thyroid nodule treatment launch into a wider medical device platform, with a longer-term push into heart rhythm procedures. The upside hinges on doctors adopting its less invasive approach and regulators staying on track, while the biggest risk is years of high spending before meaningful sales show up.Read more
AN
US$35
2.1% undervalued intrinsic discount
Fair Value
Profit Margin
11.46%
Future PE
542.34x
Price in 2029
US$43.12
Nanosecond Pulse Field Ablation Advancements Will Transform Thyroid And Cardiac Care Over Time
Pulse Biosciences is trying to replace surgery and heat-based treatments with a gentler electrical approach for thyroid nodules, and early doctor feedback suggests it may be gaining traction. The bigger upside—and biggest uncertainty—rests on whether its heart-rhythm programs prove clearly better and get paid for widely enough to justify the heavy spending needed to scale.Read more
AN
US$30.67
11.7% overvalued intrinsic discount
Fair Value
Profit Margin
11.77%
Future PE
618.22x
Price in 2029
US$37.85
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
PLSE: Cardiac Ablation Data And Index Inclusion Will Guide Fairly Valued Outlook
Fair Value: US$35 2.1% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
PLSE: Ablation Platform And Clinical Data Will Drive Access To 3b Market
Fair Value: US$30.67 11.7% overvalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Pulse Biosciences, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 06, 2026
- -1.08
- -21.04%
- -9,929.03%
- 0%
About PLSE
- Founded
- 2014
- Employees
- 116
- CEO
- WebsiteView website
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
